DalCor is currently conducting the dal-GenE study, a Phase 3 precision medicine cardiovascular outcomes trial to determine the efficacy of dalcetrapib in a genetically defined population with cardiovascular disease. The trial has enrolled 6,150 patients post-acute coronary syndrome (ACS) who have the AA genotype at rs1967309 location in the ADCY9 gene. About 20% of the population has this specific genotype. In retrospective analysis of previous trials these patients were identified to have a potentially improved cardiovascular outcome when treated with dalcetrapib.

DalCor has world-wide exclusive rights to develop and commercialize dalcetrapib and CETP inhibitors for the treatment of cardiovascular diseases in patients who have one or more improved response genotypes through at least 2034. The company has a global presence with offices in Canada, Switzerland, the United Kingdom, and the United States.